Lord Abbett & CO. LLC Sells 11,023 Shares of United Therapeutics Corporation $UTHR

Lord Abbett & CO. LLC reduced its position in United Therapeutics Corporation (NASDAQ:UTHR) by 4.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 258,049 shares of the biotechnology company’s stock after selling 11,023 shares during the quarter. Lord Abbett & CO. LLC owned about 0.60% of United Therapeutics worth $125,734,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of UTHR. Torren Management LLC bought a new position in shares of United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management boosted its position in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC boosted its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. boosted its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics in the fourth quarter valued at approximately $31,000. 94.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on UTHR shares. Bank of America raised their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. UBS Group raised their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Price Performance

UTHR stock opened at $545.96 on Friday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The stock has a market cap of $23.18 billion, a PE ratio of 20.15, a P/E/G ratio of 1.78 and a beta of 0.57. The firm has a 50 day simple moving average of $566.75 and a two-hundred day simple moving average of $521.34.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the prior year, the firm earned $6.63 EPS. United Therapeutics’s quarterly revenue was down 1.6% on a year-over-year basis. On average, research analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $9,956,712.48. The trade was a 34.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 634,984 shares of company stock valued at $358,175,202. 8.60% of the stock is owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.